The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 15, 2016

Filed:

Feb. 11, 2013
Applicant:

Whitehead Institute for Biomedical Research, Cambridge, MA (US);

Inventors:

Dohoon Kim, Somerville, MA (US);

David M. Sabatini, Cambridge, MA (US);

Richard Possemato, Brighton, MA (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C12N 15/113 (2010.01); A61K 45/06 (2006.01); A61K 31/145 (2006.01); A61K 31/7088 (2006.01); G01N 33/574 (2006.01); A61N 5/10 (2006.01); C12Q 1/68 (2006.01); G01N 33/50 (2006.01); G01N 33/573 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1137 (2013.01); A61K 31/145 (2013.01); A61K 31/7088 (2013.01); A61K 45/06 (2013.01); A61N 5/1001 (2013.01); A61N 5/1077 (2013.01); C12Q 1/6886 (2013.01); G01N 33/5011 (2013.01); G01N 33/573 (2013.01); G01N 33/57407 (2013.01); A61N 2005/109 (2013.01); A61N 2005/1087 (2013.01); A61N 2005/1089 (2013.01); C12N 2310/14 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/91028 (2013.01); G01N 2500/04 (2013.01); G01N 2800/52 (2013.01);
Abstract

In some aspects, methods of inhibiting survival or proliferation of a tumor cell are provided, the methods comprising inhibiting the glycine cleavage system (GCS) of the tumor cell. In some aspects, methods of treating a subject in need of treatment for a tumor, the method comprising inhibiting the GCS in the tumor. In some embodiments, the methods comprise contacting a tumor cell or tumor with a GCS inhibitor. In some embodiments, the tumor cell or tumor has elevated expression of serine hydroxymethyltransferase 2 (SH1VIT2). In some aspects, methods of identifying a tumor cell or tumor that is sensitive to inhibiting the GCS are provided, the methods comprising determining whether the tumor cell or tumor overexpresses SHMT2. In some aspects, methods of identifying a candidate anti-cancer agent are provided, the methods comprising identifying or modifying a GCS inhibitor.


Find Patent Forward Citations

Loading…